Shoulder Innovations, Inc. (SI) Q1 2026 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call highlighted strong financial performance with a 65% YoY revenue increase and improved gross margins. Despite increased expenses and losses, the company showed significant growth in implant volume and maintained a strong cash position. The Q&A revealed conservative guidance but high confidence in sustained growth, supported by new product development and strategic partnerships. While management avoided specific profitability timelines, the overall sentiment was positive, with a focus on long-term growth potential. Given these factors, a positive stock price reaction is expected over the next two weeks.

Key Financial Performance

Net Revenue $16.7 million, an increase of 65% year-over-year and 16% sequentially. The growth was driven by rapid onboarding of new surgeons, increased utilization within the existing customer base, and achieving product milestones.

Gross Margin 77.7%, compared to 76.9% in the prior year. The improvement was driven by improved average selling prices (ASPs) and benefits from cost reduction programs.

Selling, General and Administrative (SG&A) Expenses $18.2 million, compared to $10.5 million in the prior year. The increase was primarily driven by increased headcount in the commercial organization and higher variable selling expenses.

Research and Development (R&D) Expenses $3.8 million, compared to $1.6 million in the prior year. The increase was primarily driven by investment in new product development efforts, including costs related to the robotic platform strategic partnership.

Net Loss $8.4 million, compared to a loss of $4.7 million in the prior year. The increase was primarily related to higher operating expenses.

Adjusted EBITDA Loss $7.0 million, compared to a loss of $3.5 million in the prior year. The increase was primarily related to higher operating expenses.

Cash and Cash Equivalents $108.5 million as of March 31, 2026. The cash burn in Q1 was attributed to increased inventory and asset purchases to prepare for accelerated growth.

Total Implant Volume 2,184 units, an increase of 51% year-over-year. The growth was driven by faster onboarding of new customers, quicker progression of surgeons through customer categories, and increased volume from existing surgeons.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

I-135RFX Humeral Stem: Transitioned from limited user release to full commercial launch after receiving expanded FDA clearance. Addresses primary revision and fracture total shoulder arthroplasty cases.

N22 Glenosphere: Initiated limited user release in Q1, targeting patients with allergic reactions to metal implants. Plans for full launch to be announced.

Micro-robotic solution for shoulder arthroplasty: Progressing ahead of schedule with product development. Targeting 510(k) submission in 2027. Designed to integrate with ProVoyance platform for seamless preoperative to intraoperative workflow.

Surgeon adoption: Increased adoption among new surgeons, with 134 core and contender surgeons by the end of 2025, up 61% year-over-year. Hosted 44 educational events in Q1, including a National Symposium with 70% increase in attendance.

Geographic expansion: Secured additional hospital approvals in new territories and added top talent to commercial leadership team to support scaling.

Revenue growth: Achieved Q1 net revenue of $16.7 million, a 65% year-over-year increase. Full-year 2026 revenue guidance raised to $65-$68 million, representing 37%-44% growth over 2025.

Gross margin improvement: Q1 gross margin at 77.7%, up from 76.9% in the prior year, driven by improved ASPs and cost reduction programs.

Cash management: Cash and cash equivalents at $108.5 million as of March 31, 2026. Expecting lower cash burn starting Q2 2026.

Educational initiatives: Conducted 44 SI-sponsored educational events in Q1, fostering peer-to-peer advocacy and surgeon engagement.

Clinical data registry: Enrolled over 500 patients to build real-world evidence supporting implant portfolio.

Strategic partnerships: Partnership with Interventional Systems to develop a shoulder-specific micro-robotic solution, enhancing competitive positioning.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Financial Losses: The company reported a net loss of $8.4 million in Q1 2026, compared to a loss of $4.7 million in the prior year. This increase in losses is attributed to higher operating expenses, including increased SG&A and R&D costs.

Cash Burn: The company experienced significant cash burn in Q1 2026 due to proactive inventory and asset purchases to prepare for growth. Although they expect lower cash burn in subsequent quarters, this remains a financial risk.

Operating Expenses: Selling, general, and administrative expenses increased to $18.2 million in Q1 2026 from $10.5 million in the prior year, driven by higher headcount and variable selling expenses. This could impact profitability if not managed effectively.

R&D Costs: Research and development expenses rose to $3.8 million in Q1 2026 from $1.6 million in the prior year, primarily due to investments in new product development and robotic platform partnerships. This represents a financial challenge as the company balances innovation with cost control.

Market Penetration Challenges: While the company is expanding its surgeon base and product portfolio, achieving deeper market penetration and converting surgeons from prospect to core status remains a challenge that requires sustained effort and resources.

Regulatory Risks: The company is targeting a 510(k) submission for its robotic solution in 2027. Delays or issues in obtaining regulatory approval could impact product launch timelines and revenue growth.

Seasonal Dynamics: The company anticipates lower sequential volumes in Q3 2026 due to typical industry seasonality, which could temporarily impact revenue growth.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Full Year 2026 Net Revenue Guidance: The company has raised its full-year 2026 net revenue guidance to a range of $65 million to $68 million, representing growth of 37% to 44% over 2025. This is an increase from the prior guidance range of $62 million to $65 million.

Gross Margin Outlook: The company expects gross margins to remain strong and consistent for the balance of 2026, with potential quarter-to-quarter fluctuations based on product mix and ASP. Cost-down initiatives are expected to drive further gross margin improvement as the business scales.

SG&A Expenses: SG&A expenses as a percentage of revenue are expected to increase slightly in Q2 and Q3 due to investments in geographic expansion and commercial team growth, before declining in Q4.

R&D Expenses: R&D expenses as a percentage of revenue are expected to moderate late in 2026, with continued investment in innovation programs, including the robotic platform strategic partnership.

Seasonal Dynamics: Guidance accounts for typical seasonal dynamics in the industry, with lower sequential volumes expected in Q3 before a step-up in Q4.

New Product Launches: The company plans to continue commercial launches of new products, including the I-135RFX Humeral Stem and N22 Glenosphere, which are expected to drive growth.

Robotic Platform Development: The company is targeting a 510(k) submission for its shoulder-specific micro-robotic solution in 2027, with product development progressing slightly ahead of schedule.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Can you detail the factors contributing to the sequential and year-over-year growth improvement in Q1?

A:Growth in Q1 was driven by new customer growth, volume increases from existing customers, and higher average selling prices. This was attributed to excellent execution across the organization, particularly in the commercial team, leveraging the business intelligence platform to target investments effectively.

Q:How does the Q1 performance translate into the outlook for the rest of the year?

A:The guidance provided is conservative and reflects high conviction. It considers variables like ASPs, units, and new customers. Management does not foresee any fundamental changes in the business trajectory but is taking a balanced approach due to the early stage of the year.

Q:What is the outlook for broadening the customer base and its impact on growth?

A:Management believes there is significant room for growth within the core and contender network, focusing on high-volume surgeons. They are building a platform for sustained growth, including arthroplasty and other products, which will drive additional revenues over time.

Q:What contributed to the higher-than-expected ASPs in Q1, and what is the outlook for ASPs?

A:Higher ASPs were due to targeting centers with higher prices, improved negotiation skills, and new products with higher ASPs. While new products contributed slightly in Q1, they are expected to have a more meaningful impact in the future. ASPs are expected to remain stable with some variation due to payer mix later in the year.

Q:How is the robotic system expected to contribute to the business and differentiate from competitors?

A:The robotic system is designed to be time-transparent, use existing surgical techniques, and offer a different economic model as a service rather than a capital acquisition. It is portable and provides innovation opportunities. Customer feedback has been positive, and it is expected to enhance business stickiness and market share.

Q:What factors are influencing the guidance for the year, and are there any risks or concerns?

A:Guidance reflects seasonality in Q3, potential variation in ASPs due to payer mix, and a balanced approach due to the early stage of the year. Management has prepared for above-expectation growth by investing in inventory and assets to avoid constraints.

Q:What is the outlook for gross margins and EBITDA profitability?

A:Gross margins improved in Q1 due to higher ASPs and cost reduction programs. SG&A leverage and reduced R&D spending later in the year are expected to support profitability. Management is not providing a specific timeline or revenue threshold for EBITDA profitability but aims for above-market performance.

Q:Review of Unclear Management Responses

A:Management avoided providing specific revenue thresholds or timelines for EBITDA profitability, despite being asked about it. They also did not provide detailed metrics or data to support their guidance and outlook, relying on general statements about high conviction and balanced approaches.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

SI Transcript

Shoulder Innovations, Inc. (SI) Q1 2026 Earnings Call Transcript

Positive5-13

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.